Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q2 FY2018 Earnings Presentation
17 slides from Thyrocare Technologies's earnings presentation, November 2017
Slide 1: Thyrocare Technologies Limited Q2-FY18 Presentation
Thyrocare Technologies Limited Q2-FY18 Presentation
Slide 2: Disclaimer
Disclaimer • This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informat
Slide 3: Transition to IndAS (Indian Accounting Standards)
Transition to IndAS (Indian Accounting Standards) Six months ended Quarter ended Key IndAS Adjustments: [Rs. in million] 30 September 2016 30 September 2016 • Re-imbursement of advertisement expenses by shareholders – Non reciprocal contributions Consolidated Standalone Consolidated Standalone recei
Slide 4: Consolidated Financials
Consolidated Financials Thyrocare Technologies Limited [Consolidated] Thyrocare Technologies Limited [Consolidated] P&L Statement (INR mn, except per share data) Balance Sheet (INR mn) Particulars Year to Date YoY Growth 3 months ended YoY Growth 30 Sep 17 30 Sep 16 30 Sep 17 30 Sep 16 Particulars 3
Slide 5: Thyrocare Standalone
Thyrocare Standalone Thyrocare’
Slide 6: Standalone Financials
Standalone Financials Thyrocare Technologies Limited Thyrocare Technologies Limited Standalone P&L (INR mn, except for per share data) Balance sheet data (INR mn) Particulars Year to Date YoY Growth 3 months ended YoY Growth Particulars 30 Sep 17 30 Sep 16 30 Sep 17 30 Sep 16 30 Sep 17 30 Sep 16 Rev
Slide 7: YTD Performance Highlights - Thyrocare
YTD Performance Highlights - Thyrocare • Six months and Quarterly standalone net profit was INR 466.23 million and INR 234.42 million. The normalized six months and quarterly net profit for the current period after adjusting for the reimbursement towards advertisement from the selling shareholder wa
Slide 8: Key Financial Trends - Thyrocare
Key Financial Trends - Thyrocare Revenue (INR mn) EBITDA (INR mn) 357.6 821.4 817.9 823.6 338.8 734.1 313.0 298.7 645.2 656.9 261.3 259.7 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 44% EBITDA Margin(%) 41% 41% 41% 40% 38% Q1 - FY17 Q2 - FY17 Q3 - FY17 Q4 - FY17 Q1 - FY18 Q2 - FY18 # Previous period
Slide 9: Key Operating Metrics – Business Lines
Key Operating Metrics – Business Lines Revenue Breakup (INR mn) Volume Breakup (‘000 Samples) Q2-FY18 167 238 17 341 Q2-FY18 126.2 374.4 219.5 3,362.3 Q1-FY18 188 227 19 328 Q1-FY18 146.9 357.0 237.5 3,276.4 Q4-FY17 185 243 20 313 Q4-FY17 149.7 376.9 253.4 3,152.9 Q3-FY17 129 177 16 278 Q3-FY17 99.9
Slide 10: Key Operating Metrics – Regional Breakup
Key Operating Metrics – Regional Breakup Value Breakup (INR mn) Volume Breakup (mn Samples) 1HFY18 432.2 395.8 425.8 264.1 1HFY18 1.98 2.35 1.86 1.89 1HFY17 309.0 356.7 369.8 228.6 1HFY17 1.63 2.18 1.56 1.74 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Nort
Slide 11: Operating Data
Operating Data Thyrocare Technologies Limited (Rs. in million, except per share data) Year-on-Year Year-on-Year Particulars Year to Date 3 months ended Growth (%) Growth (%) September 30, September 30, September 30, September 30, 2017 2016 2017 2016 B2B revenue (in million) 1,133.68 995.78 14% 579.2
Slide 12: Nueclear Standalone
Nueclear Standalone Nueclear
Slide 13: Standalone Financials - Nueclear
Standalone Financials - Nueclear Nueclear Healthcare Limited Nueclear Healthcare Limited Standalone P&L (INR mn) Balance sheet data (INR mn) Particulars Year to Date # YoY Growth 3 months ended # YoY Growth Particulars 30 Sep 17 #30 Sep 16 30 Sep 17 #30 Sep 16 30 Sep 17 30 Sep 16 Revenue from operat
Slide 14: YTD Performance Highlights - Nueclear
YTD Performance Highlights - Nueclear • Six months and Quarterly standalone EBITDA of INR 19.36 million and INR 15.41 million. • Six months and Quarterly standalone revenue from operations of INR 118.66 million and INR 62.50 million, up 32% (Normalized for the adjustment of revenue/ cost of imaging
Slide 15: Key Financial Trends - Nueclear
Key Financial Trends - Nueclear Revenue (INR mn) EBITDA (INR mn) 62.5 15.4 56.2 47.4 46.8 47.6 42.3 4.3 4.0 1.8 1.8 0.3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 EBITDA Margin 25% 10% 7% 4% 4% 1% Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18
Slide 16: Center Level and Operating Metrics
Center Level and Operating Metrics Nueclear Healthcare Limited (Rs. in million, except number of scans) Year-on-Year Year-on-Year Particulars Year to Date 3 months ended Growth (%) Growth (%) September 30, September 30, September 30, September 30, 2017 2016 2017 2016 Revenue PETCT wise 110.91 79.75
Slide 17: Thank You
Thank You O Think Thyroid. Think Thyrocare. Nue clear NATIONWIDE NETWORKED
Thyrocare Technologies — Q2 FY2018 Earnings Presentation on 6ix